Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 326

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 326
---
 favourable treatment in obtaining or retaining business, or to pay for 
 favourable treatment already secured.                                                                                                                                                                                                                |

| (b) | Neither the Company nor, to the knowledge of the Company, any director, officer, employee, agent, distributor,                                                                                                                                  
 consultant, affiliate or other person acting on behalf of the Company is (i) or in the past five years has been, under administrative, civil or criminal investigation, indictment, information, suspension, debarment or audit (other than a   
 routine contract audit) by any Party, in connection with alleged or possible violations of the Anti-Corruption Laws; or (ii) has within the past five years received notice from, or made a voluntary disclosure to, the Royal Canadian Mounted 
 Police or other Governmental Entity regarding alleged or possible violations of the Anti-Corruption Laws.                                                                                                                                       |

| (c) | To the knowledge of the Company, neither the Company, nor any director, employee, affiliate or agent of the                                                                                                                            
 Company, or any person acting on the Company’s or its Subsidiary’s behalf, has, in connection with, or otherwise relating to, the operation of the Company’s business, engaged in any activity or conduct that has resulted in or will 
 result in a violation of any applicable antitrust or competition laws.                                                                                                                                                                 |

| (d) | The Company, its Subsidiary and, to the knowledge of the Company, their respective directors, officers,                                                                                                                                   
 employees, agents and other persons acting on behalf of the Company or its Subsidiary, are and have at all times been in material compliance with all applicable anti-money laundering laws, rules, and regulations, including anti-money 
 laundering-related government guidance (collectively, “AML Laws”). There is no pending investigation, inquiry or enforcement action against the Company, its Subsidiary or, to the knowledge of the Company, any of their respective      
 officers, directors or employees relating to any violation or potential violation of any AML Law related to the Company’s business.                                                                                                       |

| 35. | Sanctions |

| (a) | Neither the Company nor its Subsidiary nor, to the knowledge of the Company, their respective directors,                                                                                                                                                  
 officers, employees, agents or other persons acting on behalf of the Company or its Subsidiary are, or are directly or indirectly owned, held or controlled by or on behalf of, any person or persons listed on any list of designated persons subject to 
 international sanctions or trade embarg